Generate Biomedicines, Inc. Common Stock (GENB) - Total Assets
Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) holds total assets worth $625.74 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Generate Biomedicines, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
Generate Biomedicines, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Generate Biomedicines, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Generate Biomedicines, Inc. Common Stock for net asset value and shareholders' equity analysis.
Generate Biomedicines, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Generate Biomedicines, Inc. Common Stock's total assets of $625.74 Million consist of 71.0% current assets and 29.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Generate Biomedicines, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Generate Biomedicines, Inc. Common Stock worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Generate Biomedicines, Inc. Common Stock's current assets represent 71.0% of total assets in 2025, a decrease from 78.6% in 2024.
- Cash Position: Cash and equivalents constituted 36.8% of total assets in 2025, up from 34.0% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Generate Biomedicines, Inc. Common Stock Competitors by Total Assets
Key competitors of Generate Biomedicines, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
ZAI LAB LTD0000006
F:1ZLB
|
Germany | €1.10 Billion |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.78 Billion |
Generate Biomedicines, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.17 | - | - |
| Quick Ratio | 9.17 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $477.00 Million | - | - |
Generate Biomedicines, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Generate Biomedicines, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.20 |
| Latest Market Cap to Assets Ratio | 5.00 |
| Asset Growth Rate (YoY) | -36.3% |
| Total Assets | $330.18 Million |
| Market Capitalization | $1.65 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Generate Biomedicines, Inc. Common Stock's assets at a significant premium (5.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Generate Biomedicines, Inc. Common Stock's assets decreased by 36.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Generate Biomedicines, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $330.18 Million | -36.29% |
| 2024-12-31 | $518.26 Million | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more